Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Japan Medical Dynamic Marketing, Inc. (7600.T)
Tokyo, JP
Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including surgical nails, screws, and plates, engineered for implantation at fracture sites. JMDM also offers joint prostheses, which are designed to replace compromised natural joints and restore functions impaired by disease or injury. Additionally, the company supplies spinal stabilization systems for operations addressing spinal instability, as well as synthetic bone grafts used in the treatment of bone fractures, tumors, and other structural deficiencies. These specialized medical solutions are provided to healthcare professionals and hospitals. Founded in 1973, the firm's headquarters are located in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.90% | -13.46% | -17.73% | -8.72% | -10.71% | -9.46% | -18.18% | -50.98% | -78.75% | -38.86% | -85.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-4.8% Q1'26: -10.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+157.0% ★ Q1'26: +98.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-2.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+2.4% Q1'26: +0.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+1.2% Q1'26: +0.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.68× Q1'26: 3.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.02B
est: 13.85B (-6.0%)
|
13.63B
est: 13.75B (-0.9%)
|
14.81B
est: 14.78B (+0.2%)
|
16.73B
est: 16.60B (+0.8%)
|
18.08B
est: 18.50B (-2.3%)
|
16.74B
est: 16.80B (-0.4%)
|
19.19B
est: 18.80B (+2.1%)
|
21.31B
est: 21.50B (-0.9%)
|
23.18B
est: 23.40B (-0.9%)
|
25.11B
est: 25.20B (-0.3%)
|
24.50B
24.50B – 24.50B
-2.8% YoY
|
25.30B
25.30B – 25.30B
+3.3% YoY
|
26.50B
26.50B – 26.50B
+4.7% YoY
|
| EBITDA |
2.57B
est: 2.16B (+18.6%)
|
2.64B
est: 2.15B (+23.1%)
|
3.10B
est: 2.31B (+34.5%)
|
3.45B
est: 2.59B (+33.2%)
|
4.09B
est: 2.89B (+41.6%)
|
3.47B
est: 2.62B (+32.4%)
|
4.21B
est: 2.94B (+43.3%)
|
3.35B
est: 3.36B (-0.3%)
|
3.27B
est: 3.65B (-10.4%)
|
1.40B
est: 3.35B (-58.1%)
|
3.26B
3.26B – 3.26B
-2.8% YoY
|
3.36B
3.36B – 3.36B
+3.3% YoY
|
3.52B
3.52B – 3.52B
+4.7% YoY
|
| EBIT |
1.38B
est: 1.15B (+19.4%)
|
1.70B
est: 1.14B (+48.9%)
|
1.86B
est: 1.23B (+51.1%)
|
2.29B
est: 1.38B (+65.7%)
|
2.70B
est: 1.54B (+75.3%)
|
2.08B
est: 1.40B (+48.5%)
|
2.78B
est: 1.56B (+77.8%)
|
1.79B
est: 1.79B (0.0%)
|
1.67B
est: 1.95B (-14.3%)
|
-267.05M
est: 1.59B (-116.8%)
|
1.55B
1.55B – 1.55B
-2.8% YoY
|
1.60B
1.60B – 1.60B
+3.3% YoY
|
1.67B
1.67B – 1.67B
+4.7% YoY
|
| Net Income |
800.55M
est: 955.94M (-16.3%)
|
1.13B
est: 1.10B (+3.0%)
|
1.43B
est: 1.32B (+7.9%)
|
1.98B
est: 1.56B (+27.5%)
|
2.16B
est: 2.00B (+8.5%)
|
1.66B
est: 1.50B (+11.1%)
|
2.14B
est: 2.00B (+7.0%)
|
1.42B
est: 1.45B (-1.9%)
|
1.27B
est: 1.68B (-24.4%)
|
-461.80M
est: 1.30B (-135.5%)
|
429.45M
429.45M – 429.45M
-67.0% YoY
|
479.51M
479.51M – 479.51M
+11.7% YoY
|
650.76M
650.76M – 650.76M
+35.7% YoY
|
| SGA |
2.15B
est: 3.20B (-32.8%)
|
2.34B
est: 3.18B (-26.4%)
|
2.71B
est: 3.41B (-20.7%)
|
3.23B
est: 3.84B (-15.8%)
|
3.42B
est: 4.27B (-19.9%)
|
2.59B
est: 3.88B (-33.3%)
|
3.14B
est: 4.34B (-27.8%)
|
3.99B
est: 4.97B (-19.8%)
|
4.43B
est: 5.41B (-18.1%)
|
11.53B
est: 7.42B (+55.3%)
|
7.22B
7.22B – 7.22B
-2.8% YoY
|
7.45B
7.45B – 7.45B
+3.3% YoY
|
7.81B
7.81B – 7.81B
+4.7% YoY
|
| EPS |
30.25
est: 36.30 (-16.7%)
|
42.78
est: 41.70 (+2.6%)
|
53.99
est: 50.15 (+7.7%)
|
75.17
est: 59.10 (+27.2%)
|
82.02
est: 75.80 (+8.2%)
|
63.09
est: 56.90 (+10.9%)
|
80.95
est: 75.80 (+6.8%)
|
54.03
est: 55.10 (-1.9%)
|
48.31
est: 63.90 (-24.4%)
|
-17.54
est: 49.40 (-135.5%)
|
16.30
16.30 – 16.30
-67.0% YoY
|
18.20
18.20 – 18.20
+11.7% YoY
|
24.70
24.70 – 24.70
+35.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap Value ETF DISV | 0.01% | 311.7K | 0.42% |
| 2 | Dimensional - International Small Cap ETF DFIS | 0.00% | 157.4K | 0.39% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 188.3K | 0.22% |
| 4 | iShares Core TOPIX ETF 1475.T | 0.00% | 232.5K | 0.05% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 82.0K | 0.28% |
| 6 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
| 7 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Koichi Kondo | Senior Executive Officer and Head of China Operations & Spine Business Development | — | — |
| Naoto Sawaki | Executive Officer and GM of Administration & SCM | — | — |
| Shinichi Miyata | Executive Officer and GM of Regulatory Affairs & Development Division | — | — |
| Shinji Munechika | Director of IR | — | — |
| Takeru Yamamoto | Executive Officer & Head of the Business Division | — | — |
| Takeshi Yamamoto | Executive Officer | — | — |
| Tomoyuki Yamamoto | Executive Officer, Deputy GM of the Business Division & GM of the Joint Business Department | — | — |
| Toshiyuki Hironaka | President & Director | — | male |
| Yasuaki Hidaka | Senior Executive Officer, Head of Trauma Business Development & Director | — | male |
| Yusuke Yoshida | Executive Officer & GM of Corporate Strategy Division | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7600.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
